Details for New Drug Application (NDA): 203611
✉ Email this page to a colleague
The generic ingredient in GABAPENTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Eighty-nine suppliers are listed for this compound. Additional details are available on the gabapentin profile page.
Summary for 203611
| Tradename: | GABAPENTIN |
| Applicant: | Actavis Elizabeth |
| Ingredient: | gabapentin |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | Jun 23, 2026 | TE: | AB2 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Jun 23, 2026 | TE: | AB2 | RLD: | No | ||||
Complete Access Available with Subscription
